A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors

Oncologist

Volumn 7, Issue 6, 2002, Pages 531-538

  Ryan, David P ^a,e   Puchalski, Thomas ^a   Supko, Jeffrey G ^a   Harmon, David ^a   Maki, Robert ^b   Garcia Carbonero, Rocio ^a,c   Kuhlman, Caroline ^a   Winkelman, Jennifer ^a   Merriam, Priscilla ^c   Quigley, Travis ^c   Jimeno, Jose ^d   Manola, Judith ^c   Demetri, George D ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d PHARMAMAR S A   (Spain)

^e MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

C kit; Cancer; Chemotherapy; Clinical trials; Human studies

Indexed keywords

TRABECTEDIN;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; CANCER RESISTANCE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HEMATOLOGIC DISEASE; HUMAN; LEUKOPENIA; LIVER TOXICITY; MALE; MULTICENTER STUDY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; AREA UNDER CURVE; DIOXOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; INFUSIONS, INTRAVENOUS; ISOQUINOLINES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME;

EID: 0036913513     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.7-6-531     Document Type: Review

References (36)

1. Miettinen M, Lasota J. Gastrointestinal stromal tumors - Definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001;438:1-12.
2. Rubin BP, Singer S, Tsao C et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001;61:8118-8121.
3. Ernst SI, Hubbs AE, Przygodzki RM et al. KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors. Lab Invest 1998;78:1633-1636.
4. Lasota J, Jasinski M, Sarlomo-Rikala M et al. Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 1999;154:53-60.
5. Taniguchi M, Nishida T, Hirota S et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 1999;59:4297-4300.
6. Lux ML, Rubin BP, Biase TL et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 2000;156:791-795.
7. Joensuu H, Roberts PJ, Sarlomo-Rikala M et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052-1056.
8. DeMatteo RP, Lewis JJ, Leung D et al. Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51-58.
9. Pierie JP, Choudry U, Muzikansky A et al. The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg 2001;136:383-389.
10. Goss GA, Merriam P, Manola J et al. Clinical and pathological characteristics of gastrointestinal stromal tumors (GISTs). Proc Am Soc Clin Oncol 2000;19:2203a.
11. Sakai R, Rinehart KL, Guan Y et al. Additional antitumor ecteinascidins from a Caribbean tunicate: Crystal structures and activities in vivo. Proc Natl Acad Sci USA 1992;89:11456-11460.
12. Izbicka E, Lawrence R, Raymond E et al. In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. Ann Oncol 1998;9:981-987.
13. Pommier Y, Kohlhagen G,Bailly C et al. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 1996;35:13303-13309.
14. Moore 2nd BM, Seaman FC, Hurley LH. NMR-based model of an ecteinascidin 743-DNA adduct. J Am Chem Soc 1997;119:5475-5476.
15. Takebayashi Y, Pourquier P, Zimonjic DB et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 2001;7:961-966.
16. Jin S, Gorfajn B, Faircloth G et al. Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc Natl Acad Sci USA 2001;97:6775-6779.
17. Minuzzo M, Marchini S, Broggini M et al. Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc Natl Acad Sci USA 2000;97:6780-6784.
18. Ryan DP, Supko JG, Eder JP et al. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin Cancer Res 2001;7:231-242.
19. Delaloge S, Yovine A, Taamma A et al. Ecteinascidin-743: A marine-derived compound in advanced, pretreated sarcoma patients - Preliminary evidence of activity. J Clin Oncol 2001;19:1248-1255.
20. Taamma A, Misset JL, Riofrio M et al. Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J Clin Oncol 2001;19:1256-1265.
21. Villalona-Calero MA, Eckhardt SG, Weiss G et al. A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies. Clin Cancer Res 2002;8:75-85.
22. Mizuta E, Tsubotani A. Preparation of mean drug concentration - Time curves in plasma. A study on the frequency distribution of pharmacokinetic parameters. Chem Pharm Bull (Tokyo) 1985;33:1620-1632.
23. Lam FC, Hung CT, Perrier DG. Estimation of variance for harmonic mean half-lives. J Pharm Sci 1985;74:229-231.
24. Nakahara M, Isozaki K, Hirota S et al. A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors. Gastroenterology 1998;115:1090-1095.
25. Hirota S, Isozaki K, Nishida T et al. Effects of loss-of-function and gain-of-function mutations of c-kit on the gastrointestinal tract. J Gastroenterol 2000;35(suppl 12):75-79.
26. Hirota S, Nishida T, Isozaki K et al. Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours. J Pathol 2001;193:505-510.
27. Baker LH, Frank J, Fine G et al. Combination chemotherapy using adriamycin, DTIC, cyclophosphamide, and actinomycin D for advanced soft tissue sarcomas: A randomized comparative trial. A phase III, Southwest Oncology Group Study (7613). J Clin Oncol 1987;5:851-861.
28. Borden EC, Amato DA, Rosenbaum C et al. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol 1987;5:840-850.
29. Antman KH, Ryan L, Elias A et al. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol 1989;7:126-131.
30. Edmonson JH, Ryan LM, Blum RH et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993;11:1269-1275.
31. Antman K, Crowley J, Balcerzak SP et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993;11:1276-1285.
32. Le Cesne A, Antoine E, Spielmann M et al. High-dose ifosfamide: Circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 1995;13:1600-1608.
33. Blanke CD, von Mehren M, Joensuu H et al. Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI571, in patients (pts) with unresectable or metastatic gastrointestinal stromal tumors (GISTS) expressing c-KIT (CD117). Proc Am Soc Clin Oncol 2001;20:1a.
34. van Kesteren C, Cvitkovic E, Taamma A et al. Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study. Clin Cancer Res 2000;6:4725-4732.
35. Plaat BE, Hollema H, Molenaar WM et al. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: Differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol 2000;18:3211-3220.
36. Erba E, Bergamaschi D, Bassano L et al. Isolation and characterization of an IGROV-1 human ovarian cancer cell line made resistant to Ecteinascidin-743 (ET-743). Br J Cancer 2000;82:1732-1739.